Testosterone Cypionate Dosing for Older Adults (50 to 64): Evidence-Based Guide

Editorial evidence status: This page was reconciled to the current Depo-Testosterone label, the Endocrine Society and AUA guidelines, TRAVERSE, and the cited dose-response study on August 29, 2026. Medical review is pending. It does not select an individual dose or injection route.

Start With the Diagnosis, Not an Age-Based Dose

Testosterone should not be prescribed for fatigue, weight gain, or normal aging on the basis of one laboratory result. The Endocrine Society recommends diagnosing hypogonadism only when compatible symptoms or signs occur with unequivocally and consistently low testosterone. It recommends a fasting morning total testosterone measurement, repeated on another morning, with free testosterone assessment when total testosterone is near the lower limit or sex-hormone-binding globulin may distort interpretation [1].

The current Depo-Testosterone label likewise requires confirmation that serum testosterone is below the normal range on at least two separate mornings before treatment begins. It also states that safety and efficacy for age-related hypogonadism have not been established [2]. Being 50, 58, or 64 is therefore not itself an indication and does not determine a starting dose.

Luteinizing hormone and follicle-stimulating hormone help distinguish primary testicular failure from a pituitary or hypothalamic cause. That distinction matters because treatment, fertility planning, and additional evaluation can differ [1].

What the Label and Guidelines Actually Say About Dose

The FDA-approved Depo-Testosterone label gives a broad replacement range of 50 to 400 mg by intramuscular injection every two to four weeks and says dosage should be adjusted to the patient's response and adverse reactions [2]. A broad label range is not a prescription for every patient.

The Endocrine Society guideline discusses commonly used shorter-acting intramuscular regimens and emphasizes achieving the mid-normal range while accounting for pharmacokinetics, adverse effects, treatment burden, and patient preference [1]. The AUA similarly recommends the minimum dose needed to reach the middle portion of the laboratory reference range and improve the symptoms or signs attributed to testosterone deficiency [3].

These sources do not establish that every adult aged 50 to 64 should start at 50 mg, that cardiovascular risk automatically requires the lowest dose, or that a dose should rise by exactly 25 mg on a fixed schedule. Prescribers choose a formulation and interval, then adjust after the patient has reached an appropriate assessment point.

Age, Route, and Measurement Boundary Matrix

This crosswalk prevents three common evidence transfers: converting a broad label range into an age-specific prescription, treating an off-label route as a labeled one, and applying a gel cardiovascular trial as if it directly tested testosterone cypionate injections.

Time the Testosterone Measurement Correctly

An injected testosterone result is meaningful only in relation to the injection schedule. For testosterone cypionate or enanthate, the Endocrine Society recommends measuring serum testosterone midway between injections. Its monitoring table recommends adjusting dose or frequency when a mid-interval value is above 600 ng/dL or below 350 ng/dL [1]. That is not the same as a universal trough target.

The AUA uses a general physiologic target of 450 to 600 ng/dL and recommends checking short-acting injectable therapy only after enough cycles have passed to assess the regimen, then measuring testosterone every 6 to 12 months once stable [3]. Different guidelines can therefore use different operational ranges and timing. The prescriber should document which approach is being followed rather than mixing a trough from one protocol with a target from another.

Symptoms matter alongside the number. If testosterone normalizes but the original symptoms do not improve, the AUA recommends discussing cessation rather than escalating indefinitely [3].

Injection-Cycle Monitoring Record

Use one row for each decision-making laboratory draw or follow-up. The record is not a dosing calculator; it makes the regimen, measurement timing, response, and safety findings auditable.

Do not use an isolated entry to self-adjust the injection. Bring the record to the clinician so a result drawn at the wrong point in the cycle is not “corrected” with an unnecessary dose change.

Hematocrit Is a Major Dose-Limiting Check

Testosterone can increase red-cell production. Controlled dose-response research found a greater erythropoietic response in older men than younger men at comparable testosterone exposures [6]. That supports careful monitoring, but it does not justify an invented age-specific dose formula.

The Endocrine Society recommends measuring hematocrit at baseline, three to six months after starting, and then annually. If hematocrit exceeds 54%, treatment should be stopped until it returns to a safe level; the patient should be evaluated for hypoxia and sleep apnea, and therapy may be restarted at a reduced dose [1]. The AUA also uses 54% as the intervention threshold [3].

A baseline value, smoking, lung disease, sleep apnea, altitude, dehydration, and the formulation all affect interpretation. Routine therapeutic phlebotomy should not be presented as a substitute for finding the cause and correcting excessive testosterone exposure.

Prostate, Blood Pressure, and General Follow-Up

Prostate monitoring should follow shared decision-making and the patient's age and risk. For men who choose monitoring, the Endocrine Society recommends baseline assessment and repeat evaluation three to 12 months after starting. Urologic consultation is recommended for a confirmed PSA above 4 ng/mL, an increase greater than 1.4 ng/mL during the first year, a prostate abnormality on examination, or substantial worsening of lower urinary tract symptoms [1].

In February 2025, FDA removed cardiovascular-risk language from testosterone boxed warnings after reviewing TRAVERSE, but required blood-pressure warnings across testosterone products based on ambulatory blood-pressure studies [5]. Blood pressure should therefore be assessed rather than assuming testosterone is cardiovascularly neutral.

Follow-up also covers symptom response, adverse effects, adherence, edema, sleep-apnea symptoms, fertility goals, and formulation-specific issues. Estradiol, ECGs, lipid panels, DXA scans, and other tests are not automatic at every visit for every patient; they are ordered when the history, symptoms, comorbidities, or another guideline indicates them.

What TRAVERSE Can and Cannot Prove

TRAVERSE enrolled 5,246 men aged 45 to 80 who had symptoms, two fasting testosterone values below 300 ng/dL, and established or high cardiovascular risk. Participants received 1.62% testosterone gel or placebo, not testosterone cypionate injections [4].

The primary cardiovascular endpoint occurred in 7.0% of the testosterone group and 7.3% of the placebo group. Testosterone was noninferior to placebo for the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial also observed higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group [4].

The correct conclusion is narrow: in that studied population and gel protocol, major cardiovascular events met the prespecified noninferiority criterion. TRAVERSE does not prove that all testosterone formulations, doses, or patients have identical risk. It also does not create a requirement for a baseline ECG or cardiology clearance in every patient; those decisions depend on clinical history and current symptoms.

Intramuscular Versus Subcutaneous Injection

The current testosterone cypionate label specifies deep intramuscular injection [2]. Subcutaneous use is off-label. Small studies and clinical practice have explored subcutaneous testosterone, but they do not convert the cypionate label to a subcutaneous indication or establish that it produces lower hematocrit or fewer reactions in older adults.

Injection site, needle, syringe, dose volume, and technique should come from the prescription, product instructions, and training by the dispensing clinician or pharmacist. A website should not prescribe a universal needle gauge or convert a regimen from intramuscular to subcutaneous administration.

Comorbidities Do Not Create Automatic Dose Formulas

Obesity, type 2 diabetes, sleep apnea, chronic kidney disease, anticoagulant use, and cardiovascular disease all affect risk assessment. None creates a validated rule such as “increase the dose 20% for obesity” or “reduce it 50% for chronic kidney disease.”

The Depo-Testosterone label warns that androgens may alter anticoagulant activity and may lower blood glucose and insulin requirements in people with diabetes [2]. That calls for medication review and appropriate monitoring, not a predetermined testosterone adjustment.

The Endocrine Society recommends against starting therapy in men planning fertility in the near term or with breast or prostate cancer, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within six months, or thrombophilia [1]. Individual product contraindications and warnings must also be checked.

Routine aromatase-inhibitor treatment is not an evidence-based consequence of obesity or a single estradiol number. Breast symptoms or gynecomastia require evaluation; adding anastrozole changes the risk-benefit equation and should not be reduced to an internet dosing rule.

Stopping Testosterone Cypionate

There is no major guideline-supported universal taper that reduces testosterone cypionate by 25% every four weeks. Exogenous testosterone can suppress the hypothalamic-pituitary-gonadal axis and sperm production, so stopping may be followed by low-testosterone symptoms while endogenous function recovers. Recovery varies with the underlying diagnosis, treatment duration, dose, age, and testicular function.

The reason for stopping determines the plan. Lack of benefit despite normalized levels, fertility goals, erythrocytosis, an adverse event, or a new contraindication are not interchangeable. The prescriber may stop, reduce, change the interval, change formulation, or arrange specialist evaluation. A fixed taper should not be presented as proven to restore the axis faster.

Storage and Product Handling

Depo-Testosterone is supplied in 100 mg/mL and 200 mg/mL strengths. The current label directs storage at 20°C to 25°C (68°F to 77°F), with permitted excursions described in the label, and says warming and rotating the vial between the palms can redissolve crystals that form below the recommended range [2].

Use the exact vial label and pharmacy instructions. Do not assume every testosterone cypionate presentation is a multidose vial or apply a universal after-opening date without checking the product and dispensing instructions.

Bottom Line

For an adult aged 50 to 64, safe testosterone cypionate treatment begins with a confirmed diagnosis and an identified cause—not an age-based dose. The approved route is intramuscular, dose and interval are individualized, testosterone is measured at the correct point in the injection cycle, and hematocrit, prostate risk, blood pressure, symptoms, adverse effects, and fertility goals guide follow-up.